Cargando…
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
Autores principales: | Germa, C., Miller, M., Mukhopadhyay, P., Hewes, B., Caponigro, G., Scherer, S. J., Hirawat, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834041/ https://www.ncbi.nlm.nih.gov/pubmed/28838206 http://dx.doi.org/10.1093/annonc/mdx226 |
Ejemplares similares
-
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
por: Chin, K., et al.
Publicado: (2017) -
Cross-over—it's a feature, not a bug
por: Engelsberg, A.
Publicado: (2015) -
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
por: Novotny, J. F., et al.
Publicado: (2016) -
Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
por: Gaspar, N, et al.
Publicado: (2018) -
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)